B细胞淋巴瘤嵌合抗原受体T细胞治疗前的桥接放疗:一项ILROG多中心研究
该多中心回顾性研究纳入2018至2020年10家机构172例接受桥接放疗后行CAR-T的复发/难治B细胞淋巴瘤患者,评估桥接放疗对疗效与毒性的影响。中位随访31.3个月,2年无进展生存率和总生存率分别为38%和53%,综合桥接放疗与更优的无进展生存和总生存相关。
要点
- 桥接放疗后≥3级放疗毒性发生率为2%,≥3级细胞因子释放综合征为9%,≥3级免疫效应细胞相关神经毒性综合征为24%。
- 综合桥接放疗与更优的无进展生存(HR 0.38;P < .001)和总生存(HR 0.48;P = .011)相关。
- 桥接放疗后乳酸脱氢酶正常化者较桥接放疗后乳酸脱氢酶仍高者无进展生存和总生存更优。
核心结论
- 在这一高危队列中,CAR-T前桥接放疗的毒性谱可接受,与历史对照相比临床结局良好。
- 综合桥接放疗和桥接放疗后乳酸脱氢酶正常化可能与更优的无进展生存和总生存相关。
研究设计与样本
- 多中心回顾性研究,纳入2018至2020年10家机构接受桥接放疗后行CAR-T的复发/难治B细胞淋巴瘤患者。
- 共172例患者(其中168例为大B细胞淋巴瘤),接受阿基仑赛(73%)、替沙仑赛(24%)或brexucabtagene autoleucel(2%)。
- 桥接放疗毒性按不良事件通用术语标准5.0版分级,细胞因子释放综合征和免疫效应细胞相关神经毒性综合征按美国移植与细胞治疗学会共识指南分级。
主要发现
- 白细胞采集时,74%的患者为晚期疾病,39%有≥10cm的巨块型病变。
- 39%接受综合桥接放疗,35%接受桥接全身治疗。
- 全部患者中,≥3级桥接放疗毒性发生率为2%(含1例5级毒性),≥3级细胞因子释放综合征为9%,≥3级免疫效应细胞相关神经毒性综合征为24%。
- 中位随访31.3个月,2年无进展生存率为38%,2年总生存率为53%。
- 多变量分析中,综合桥接放疗与更优的无进展生存相关(HR 0.38;P < .001),也与更优的总生存相关(HR 0.48;P = .011)。
关键数值与推荐
- 桥接放疗后乳酸脱氢酶正常化者(桥接放疗前乳酸脱氢酶高、桥接放疗后乳酸脱氢酶正常)较桥接放疗后乳酸脱氢酶仍高者无进展生存和总生存更优,与基线乳酸脱氢酶正常者无进展生存和总生存相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refractory B-cell lymphomas (BCLs) who received Br-RT followed by CAR-T from 2018 to 2020 across 10 institutions. Br-RT toxicities were graded per Common Terminology Criteria for Adverse Events version 5.0, and cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) per American Society for Transplantation and Cellular Therapy Consensus Guidelines. One hundred seventy-two patients (168 large BCL) received Br-RT before axicabtagene ciloleucel (73%), tisagenlecleucel (24%), or brexucabtagene autoleucel (2%). At leukapheresis, most patients (74%) had advanced-stage disease and 39% had bulky disease measuring ≥10cm. Comprehensive Br-RT was administered to 39% and bridging systemic therapy to 35%. Among all patients, grade ≥3 Br-RT toxicity occurred in 2% (1 grade 5 toxicity), grade ≥3 CRS in 9%, and grade ≥3 ICANS in 24%. Median follow-up was 31.3 months. Two-year progression-free survival (PFS) and overall survival (OS) were 38% and 53%, respectively. On multivariable analysis, comprehensive Br-RT was associated with superior PFS (hazard ratio [HR], 0.38; P < .001) and OS (HR, 0.48; P = .011). Patients with lactate dehydrogenase (LDH) normalization after Br-RT (high pre-Br-RT LDH, normal post-Br-RT LDH) had superior PFS and OS compared with those with high post-Br-RT LDH and similar PFS and OS compared with those with normal baseline LDH. In this particularly high-risk cohort, Br-RT before CAR-T demonstrates an acceptable toxicity profile with favorable clinical outcomes compared with historical controls. Comprehensive Br-RT and LDH normalization after Br-RT may be associated with superior PFS and OS.
引用
- Yegya-Raman N, Plastaras JP, Wright CM, et al. Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study. Blood Adv. 2025. PMID: 40203192. doi:10.1182/bloodadvances.2025015855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。